Most antidepressants on the market carry minimal risk of QT prolongation. Paroxetine, sertraline, fluoxetine, bupropion, vortioxetine, and vilazodone are among the options that have shown little to no clinically meaningful effect on the QT interval in studies to date. The picture is more complicated than a clean “safe” versus “dangerous” list, though, because your individual risk depends as much on your own health profile as on which pill you take.
The Low-Risk Options
Among the selective serotonin reuptake inhibitors, paroxetine stands out as having the lowest documented QT risk. A review of available studies found that paroxetine monotherapy showed no clinically significant QT prolongation in any study examined, while fluoxetine, fluvoxamine, and sertraline demonstrated a similarly low risk at standard doses.1PubMed. A comparison of the risk of QT prolongation among SSRIs For someone whose primary concern is avoiding cardiac rhythm effects, these four SSRIs represent well-studied, lower-risk territory.
Beyond the SSRIs, several other antidepressants fall into the minimal-risk category. Expert risk stratification places bupropion, duloxetine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, and agomelatine alongside most SSRIs in a low-concern tier for QT effects.2Psychopharmacology Institute. Cardiac Side Effects of Psychiatric Medications A large network meta-analysis published in The Lancet, pooling data from 29 studies covering roughly 11,000 participants, found little evidence of QT change with fluoxetine, escitalopram, bupropion, desvenlafaxine, venlafaxine, citalopram, duloxetine, vilazodone, paroxetine, trazodone, or levomilnacipran compared with placebo.3The Lancet. Comparative physiological effects of 30 antidepressant drugs: a systematic review and network meta-analysis That is a reassuring breadth of choices.
Vortioxetine deserves a specific mention because it has been through a thorough QT study, the gold-standard design regulators use to evaluate a drug’s cardiac rhythm effects. At both its standard dose and a supratherapeutic dose four times higher, vortioxetine did not prolong the QT interval beyond the threshold that would raise concern.4PubMed. Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study That kind of data is especially useful for people who need higher doses or who have other medications on board.
Mirtazapine, often prescribed for depression accompanied by insomnia or poor appetite, also appears to carry minimal QT risk. In a safety analysis comparing over 300 patients on mirtazapine with a placebo group, the average QT increase was tiny and no patient’s QT interval crossed the clinically alarming threshold.5InpharmD. Is the QTc-prolonging effect of mirtazapine dose-related? Reviews have reached the same conclusion even in overdose scenarios.
The Citalopram and Escitalopram Question
If you have looked into this topic before, you have probably encountered the FDA’s 2011 warning about citalopram. The agency recommended a maximum dose of 20 mg per day for adults over 60, citing dose-dependent QT prolongation. One study found that the prevalence of QT prolongation increased with citalopram dose, and the average QT increase was statistically significant in higher-dose groups, particularly in older patients.6PubMed Central. Evaluation of QTc prolongation and dosage effect with citalopram Health Canada extended similar dose caps to escitalopram, citalopram’s close chemical relative.
The scientific basis for those dose limits is more contested than you might expect. A study in a real-world geriatric setting found that its data did not support the FDA’s or Health Canada’s recommended maximum dosages of citalopram or escitalopram in older adults.7PubMed. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting And the Lancet network meta-analysis mentioned earlier found little evidence of QT change with either citalopram or escitalopram relative to placebo.8The Lancet. Comparative physiological effects of 30 antidepressant drugs: a systematic review and network meta-analysis In practice, many clinicians still prescribe escitalopram at moderate doses with confidence but pay closer attention to ECGs at higher doses or when other risk factors are in play. The debate has not been fully resolved, which means these two drugs sit in a gray zone rather than a clearly dangerous one.
Tricyclic Antidepressants Sit at the Other End of the Spectrum
The older tricyclic antidepressants are the class most clearly associated with QT prolongation. The Lancet meta-analysis found weak evidence of QT increases with nortriptyline and amitriptyline, the only drugs in its analysis that showed even a trend toward prolongation.9The Lancet. Comparative physiological effects of 30 antidepressant drugs: a systematic review and network meta-analysis Even “weak evidence” is notable in a context where most other antidepressants showed essentially none.
Tricyclics are particularly concerning because they hit multiple cardiac ion channels at once. Imipramine and amitriptyline block not only the potassium channel responsible for QT prolongation but also sodium and calcium channels in the heart.10Arrhythmia & Electrophysiology Review. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest That multi-channel blockade makes overdose with tricyclics particularly dangerous from a cardiac standpoint. Desipramine, another tricyclic, uses an additional trick: it triggers the heart’s potassium channels to be pulled from the cell surface and broken down, reducing the number of channels available to the heart even after the drug itself clears.11PubMed Central. Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG This is one reason tricyclics are rarely first-line choices today when safer alternatives exist.
How Antidepressants Affect Heart Rhythm in the First Place
The QT interval on an electrocardiogram reflects how long it takes the heart’s ventricles to reset electrically after each beat. That reset depends heavily on potassium channels, particularly one called hERG, which lets potassium flow out of heart cells to restore their resting charge. When a drug blocks hERG channels, the reset takes longer, and the QT interval stretches.12PubMed. Impact of antipsychotics and antidepressants drugs on long QT syndrome induction related to hERG channel dysfunction: a systematic review If the interval stretches far enough, it creates a window where the heart can fall into a chaotic rhythm called torsades de pointes, which can be fatal.
The reason most modern antidepressants carry low QT risk is simply that they do not strongly bind to hERG channels at the concentrations reached in the body at therapeutic doses. Tricyclics bind more aggressively and, as described above, affect additional channels. The newer drugs were designed with this vulnerability in mind; thorough QT studies are now a standard part of drug development, so medications that significantly prolong QT tend to get flagged or redesigned before they reach the market.
SNRIs and the Venlafaxine Wrinkle
The serotonin-norepinephrine reuptake inhibitors are generally considered low risk for QT prolongation, but venlafaxine has accumulated more concerning reports than its relatives. Rare QT prolongation has been described with venlafaxine at therapeutic doses and in overdose, while existing studies have not shown QT prolongation with desvenlafaxine, duloxetine, levomilnacipran, or vilazodone, though partly because data are still limited.13PubMed. Risk of QT/QTc prolongation among newer non-SSRI antidepressants
One nuance worth knowing: duloxetine blocks cardiac sodium channels with a potency similar to amitriptyline in laboratory experiments, something venlafaxine does not do at clinically relevant concentrations.14PubMed. Differential inhibition of cardiac and neuronal Na(+) channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine However, sodium channel blockade and QT prolongation are different cardiac risks, and duloxetine has not shown meaningful QT effects in clinical data. The sodium channel finding is more relevant to overdose toxicity than to everyday prescribing. For people choosing among SNRIs specifically, desvenlafaxine and duloxetine are likely the cleaner choices from a QT standpoint, while venlafaxine remains a reasonable option with appropriate monitoring in people who benefit from it.
Your Risk Factors Can Matter More Than the Drug
A comprehensive review of case reports involving QT prolongation and torsades de pointes found that at least one additional, well-established risk factor was present in over 92% of cases.15PubMed. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review In other words, the drug alone almost never caused the problem. The danger typically emerged when the drug landed on top of a vulnerable heart.
The risk factors that consistently show up across studies include:
- Age over 65: aging changes how the heart repolarizes and how the body metabolizes drugs.
- Female sex: women have slightly longer baseline QT intervals, leaving less margin before reaching dangerous territory.
- Existing heart disease: heart failure, prior heart attack, or structural abnormalities reduce the heart’s electrical resilience.
- Electrolyte imbalances: low potassium, magnesium, or calcium directly impair the ion channels involved in cardiac repolarization.
- Kidney or liver impairment: slower drug clearance means higher blood levels, which increases channel blockade.
- Other QT-prolonging medications: combining two or more drugs that each slightly prolong QT can push the interval past a safe threshold.
These factors are identified repeatedly in guidance documents and reviews.16American Journal of Health-System Pharmacy. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation Low potassium, in particular, has a graded dose-response relationship with severe QT prolongation, and the risk is amplified when combined with high-risk psychiatric medications.17Heart Rhythm. Exploring the link between antipsychotic and antidepressant use and severe QT prolongation If you are on a diuretic that depletes potassium, for instance, fixing the potassium level may do more for your cardiac safety than switching antidepressants.
The same comprehensive review noted that three-quarters of torsades de pointes cases occurred at therapeutic doses, not overdoses, underscoring that the patient’s underlying vulnerability is the key variable.18PubMed. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review The review also concluded there is little evidence that drug-associated QT prolongation by itself is enough to predict torsades de pointes. That does not mean the drugs are irrelevant, but it does mean the conversation should be about your total risk picture rather than fixating on one medication alone.
When ECG Monitoring Makes Sense
Not everyone starting an antidepressant needs a heart tracing. A Dutch consensus guideline on the topic recommends ECG screening before and after starting a QT-prolonging antidepressant when you already have vulnerability to QT prolongation or when two or more risk factors are present. Those risk factors include age over 65, female sex, concurrent use of another QT-prolonging drug, cardiac disease, excessive dosing, and electrolyte disturbances.19PubMed Central. Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring
If you are a 35-year-old with no heart history starting sertraline, an ECG is unlikely to tell you anything useful. If you are 70, on a water pill and an antipsychotic, and adding citalopram, the calculus changes. Clinicians also have stepped algorithms to guide what to do if monitoring reveals a prolonged QT: reduce the dose, switch to a lower-risk drug, correct electrolytes, or remove the interacting medication.20PubMed Central. A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population Having a baseline ECG before starting treatment gives you a reference point that makes later comparisons more meaningful. The general guidance from review literature is to assess and monitor electrolytes and ECGs to evaluate risks and benefits for older adults receiving agents known to prolong the QT interval.21PubMed Central. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence
Choosing an Antidepressant When You Already Have Heart Disease
If you have had a heart attack or live with heart failure, the choice of antidepressant becomes more deliberate. Sertraline has the strongest track record in this population. It has a low risk of drug-drug interactions with cardiac medications, a favorable side-effect profile, and possible beneficial effects on platelet activity, which could be an advantage after a coronary event.22PubMed. Treatment of Depression in Patients with Concomitant Cardiac Disease SSRIs broadly, and potentially SNRIs, are considered relatively safe and effective for patients with heart failure.
Tricyclics, on the other hand, are generally avoided in people with cardiac disease. Their sodium channel blockade can worsen conduction abnormalities, their anticholinergic effects can speed heart rate, and their QT-prolonging potential adds risk in hearts already electrically vulnerable. Even among SSRIs, your cardiologist and psychiatrist may want to coordinate care if you are on antiarrhythmic drugs or other medications that affect heart rhythm, since the risk is cumulative.
Supplements and Herbal Antidepressants Are Not Automatically Safer
Some people turn to St. John’s Wort as a “natural” alternative, assuming it sidesteps cardiac concerns entirely. That assumption is not fully supported. A case report documented a young woman with no structural heart abnormality or cardiac history who developed recurrent episodes of a fast heart rhythm one month after starting St. John’s Wort, which resolved when she stopped taking it.23PubMed Central. St. John’s Wort-Induced Supraventricular Tachycardia While this is a single case and a different rhythm problem than QT prolongation, it illustrates that herbal supplements are pharmacologically active and can affect the heart.
St. John’s Wort also powerfully induces liver enzymes that metabolize many drugs, which can lower blood levels of medications you are already taking, sometimes dangerously. If you are on a heart medication whose blood level needs to remain stable, adding St. John’s Wort can destabilize it. The “natural” label does not mean “no cardiac effects.”
Children and Adolescents
The pediatric population presents its own challenges. Various psychiatric medications used in children are associated with QT prolongation, yet prescribing guidelines for many of these drugs in children do not currently exist in the same detail as for adults.24PubMed Central. Psychiatric Medications and QTc Prolongation in the Pediatric Population Children’s hearts are not simply smaller versions of adult hearts; they have different baseline QT intervals and different susceptibilities. A thorough personal and family history is especially important before starting a QT-prolonging drug in a young person, since inherited long QT syndromes can be silent until triggered by a medication. Some families only learn about a genetic predisposition after a child has an adverse event on a drug that would have been uneventful for most people.
For children who need antidepressant treatment and have cardiac risk factors, the same general principles apply as in adults: prefer low-risk agents, check electrolytes, and get a baseline ECG if the clinical picture warrants it. Fluoxetine and escitalopram are the SSRIs most commonly used in pediatric depression, and both fall in the low QT-risk category in available data. When the child is also taking stimulants or antipsychotics, the cumulative QT effect of the full medication list, not just any single drug, is what matters.
Drug Combinations and the Stacking Problem
One scenario that trips people up is not any single antidepressant but the total load of QT-prolonging drugs taken together. You might be on an antidepressant with minimal QT effect, but if you also take an antibiotic like azithromycin, an antinausea drug like ondansetron, or an antipsychotic added for augmentation, each one nudges the QT interval a bit further. The risk factors identified in consensus guidelines explicitly include concurrent use of another QT-prolonging drug or a drug that affects the metabolism of a QT-prolonging drug.25PubMed Central. Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring
This is where having a pharmacist review your full medication list becomes genuinely useful, not as a formality but as a real safety check. Databases like CredibleMeds maintain lists of drugs categorized by their QT risk, and many electronic prescribing systems flag interactions automatically. If you are adding a new medication to an existing regimen that already includes one QT-prolonging drug, the interaction is worth checking even if each drug individually seems low-risk. The concern is rarely dramatic at standard doses of low-risk agents, but for someone who already has borderline electrolytes or mild kidney impairment, two “small” QT effects stacking together can cross a line neither would cross alone.